In 2021 and 2022 over 500 people benefited from our online and interactive IO educational forums. For 2024 it was time to join us in Manchester! Immuno-oncology professionals came together from across the country at this face-to-face training conference and learnt from experts in their field, in a friendly and informative environment, leaving the event with increased knowledge of cardiovascular, immune, fatigue, neurological and respiratory toxicities.
Please click here to see a full list of upcoming cancer and oncology events
Key learning outcomes
| Managing side effects | |
|
Identifying and treating immune hepatitis and nephritis IO related side effects
Dr Jo Ocen, Consultant Medical Oncologist, Velindre Cancer Centre, Velindre University NHS Trust
|
|
| Treating adverse effects | |
|
Assessing and treating fatigue resulting from immuno-oncology
Helen Grist, Immunotherapy CNS, Worcestershire Acute Hospitals NHS Trust
|
|
|
Interactive discussion: Benchmark your experience of assessing and managing toxicities
|
|
|
Feedback from interactive discussion on Benchmark your experience of assessing and managing toxicities
|
|
| Identifying toxicities | |
|
Recognising and treating neurological toxicities secondary to IO
Dr Aisling Carr, Consultant Neurologist, UCL Queen Square Institute of Neurology, University College London
|
|
|
Interactive discussion: Supporting and educating A&E and community teams to escalate immunotherapy patients appropriately
|
|
|
Feedback from interactive discussion: Supporting and educating A&E and community teams to escalate immunotherapy patients appropriately
|
|
|
Assessing and managing respiratory side effects of immuno-oncology
Dr Anna Olsson-Brown, Consultant in Medical Oncology and Clinical Director for Clinical Cancer Care, University Hospitals Sussex NHS Foundation Trust
|
|
|
Chair’s closing remarks
|
|
The speaker line-up:
Lisa Barrott has been in oncology for approximately 15 years and a UKONS member for 12 years. During this time she has worked in a variety of areas, including research, ambulatory care, Acute Oncology and Cancer of Unknown Primary; and has also undertaken different roles including clinical nurse specialist, nurse manager, Cancer Matron and Chemotherapy Nurse Consultant. Lisa currently works at University Hospitals Sussex NHS Foundation Trust as the Divisional Director of Nursing & AHPs for the Cancer Division. She works closely with Cancer Alliances, Commissioning Groups and National charities to develop services locally and nationally.
Lisa was a UKONS Board member from 2018-2203 and continues to represent UKONS on the UK SACT Board. Lisa undertook an MSc in Healthcare Practice (Advanced Practice Clinical Cancer Care) through the Royal Marsden School and St George’s University, and is a non-medical prescriber. She is currently undertaking a part-time PhD through Kings College London looking at multi-professional SACT clinics.
%20UK%20ONS%20official%20photo.JPG?width=220&height=140&rmode=&token=RxPfdbmACXytMUOt433137oKwRzvqdqKtwC8d3yPr6Y%3D)
Dr Carr was appointed as a consultant neurologist in the centre for Neuromuscular diseases, NHNN in 2016. She completed undergraduate medical education in Trinity College Dublin and Université François Rabelais, France (honors). With post-graduate training in medicine and Neurology in the Northern Ireland deanery. Her subspeciality expertise in neuromuscular diseases was developed through a Masters in myologie, Universite de Pierre et Marie Curie Paris, PhD in myasthenia epidemiology between Queen’s university Belfast and Oxford and a clinical fellowship in Peripheral Nerve in the National Hospital for Neurology and Neurosurgery, London. She is a full time clinical neurologisy with a subspecialty interest in inflammatory peripheral nerve and runs a pan-London immune checkpoint inhibitor neurotoxicity service and is the neurologist on the national HLH MST run through UCLH. Her particular clinical research interest is inflammatory neuropathy, biomarker development and understanding the toxicities of immune therapies. She is UCLH PI for ADHERE (phase 2/3 randomised control trial of efgartigimod in CIDP) and UK CI/ UCLH PI for ARDA (phase 2/3 randomised control trial for C2 complement inhibitor in MMN).
Click here to view publications.
Who came?
This face-to-face conference was ideal for NHS professionals working in immunotherapy MDTs. Attendees included:
Past attendee feedback
“This has been a really useful update on toxicities of immunotherapy”
West Hertfordshire Teaching Hospitals NHS Trust, Identifying and Treating Immuno-Oncology (IO) Adverse Effects, December 2022
“The presentations are so helpful and will help manage patients in clinical practice”
Surrey and Sussex NHS Healthcare Trust, Identifying and Treating Immuno-Oncology (IO) Adverse Effects, December 2022
“An excellent morning. Really enjoyed the balance between the (complex) science of checkpoint inhibitors and case studies that illustrated the importance of careful assessment and multi-professional working relationships”
Somerset NHS Foundation Trust, Recognising and Treating IO Side Effects, November 2021
“Excellent, relevant, worthwhile and informative. The best online forum I have attended”
University Hospitals Trust Sussex NHS Foundation Trust, Recognising and Treating IO Side Effects, November 2021
“Great session with experts who were knowledgeable and explained things very well”
Worcester Acute NHS Trust, Recognising and Treating IO Side Effects, November 2021
“Excellent. One of the best I've attended. Pitched perfectly and I understood it!”
West Hertfordshire Hospitals NHS Trust, Recognising and Treating IO Side Effects, July 2021
“I found it very friendly, and very informative. It was nice to talk to other areas before the presentations started in small groups and learn a bit about how other areas process are for triage and assessment of their patients”
Sheffield Teaching Hospitals NHS Foundation Trust, Recognising and Treating IO Side Effects, July 2021
“I am so grateful for the knowledge acquired through my first virtual conference. It was very well organised with technical support provided, very efficient. Speakers were excellent and content very appropriate and relevant”
Royal Surrey NHS Foundation Trust, Managing Side Effects of Cancer Immunotherapy, December 2020
“Informative, friendly and highly appropriate content. Really exciting day as it felt like networking and being present at a physical conference, so thank you for making it so warm and welcoming”
Western Sussex Hospitals NHS Trust, Managing Side Effects of Cancer Immunotherapy, December 2020
Why sponsor?
Interested in having your own event, managed by us?
Reach out today
Thank you for attending an event by SBK Healthcare. We are pleased to offer you on-line access to the documentation that you received at the event. This is an exclusive benefit for all of the attendees and includes additional and updated documentation.